Clinical trials: Cognitive Function, Preclinical
Alzheimer Disease, Cognitive Decline Due to Alzheimer Disease
Randomized Trial of Low-dose Naproxen in Cognitively Intact Persons at Risk of Alzheimer's Dementia
Two-year double-masked trial of over-the-counter dosage of naproxen sodium vs placebo in 200 cognitively normal participants with a parental or multiplex first-degree family history Alzheimer's disease (AD) dementia.
- Conditions
- Alzheimer Disease, Cognitive Decline Due to Alzheimer Disease, Mild Cognitive Impairment Due to Alzheimer Disease
- Trial name
- NCT02702817
- Testing
- Naproxen
- Where
- Canada
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Douglas Mental Health University Institute
Autism Spectrum Disorder, Neurofibromatosis 1
From Molecules to Cognition: Inhibitory Mechanisms in ASD and NF1
This study aims to investigate synaptic physiology and behavioral inhibition in patients with NF1 and ASD and to answer whether inhibitory deficits at these levels are modulated by lovastatin.
- Trial name
- ASD/NF1inhib (NCT03826940)
- Testing
- Lovastatin 60 MG
- Where
- Portugal
- Volunteers
- 16 people
- Sponsor
- University of Coimbra
Alzheimers Disease
A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease
The purpose of this study is to determine the effects of CNP520 on cognition, global clinical status, and underlying AD pathology, as well as the safety of CNP520, in people at risk for the onset of clinical symptoms of AD based…
- Trial name
- GS2 (NCT03131453)
- Testing
- CNP520 50mg, CNP520 15mg
- Where
- 194 sites in United States, Argentina and 23 more
- Volunteers
- 1,145 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Alzheimer Disease, Mild Cognitive Impairment (MCI)
Communication Regarding Preclinical Dementia Diagnostic and Diagnostic Disclosure Among Patients with MCI and SCD
The study investigate what information individuals with SCD or MCI and their co-participant would like to receive during pre-diagnostic counseling and diagnostic disclosure, and how this information should be conveyed.
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment (MCI), Subjective Cognitive Decline (SCD)
- Trial name
- NCT06621758
- Testing
- questionnaire
- Volunteers
- 120 people
- Sponsor
- Danish Dementia Research Centre
Mild Cognitive Impairment
Cognitive Detection of Preclinical AD: Validation Using Biomarkers
The current study aims to validate several novel cognitive tasks expected to be sensitive to brain impairment in specific anatomic regions affected in preclinical Alzheimer's disease(pAD).
- Trial name
- NCT02616679
- Where
- United States
- Volunteers
- 81 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
Mild Cognitive Impairment
PET Measures of CSF Clearance in Preclinical Alzheimer's Disease
The purpose of this study is to measure cerebrospinal fluid (CSF) clearance. CSF cushions the brain from impact and carries waste products from the brain to the bloodstream. This process is known as clearance.
- Trial name
- NCT03663387
- Where
- United States
- Volunteers
- 116 people, healthy volunteers welcome
- Sponsor
- Weill Medical College of Cornell University
Huntington Disease
Clinical Study to Monitor Plasma Levels of 24OHC in Subject with HD
A 2-year clinical longitudinal study to measure plasma concentrations of 24S-hydroxycholesterol, a brain-derived cholesterol catabolite, in subjects with Huntington disease, from the presymptomatic to the symptomatic stages.
- Trial name
- Chol-HD (NCT04257513)
- Testing
- Brain MRI
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Sleep Disturbances, Aging
Low-intensity Hippocampal Transcranial Ultrasound Stimulation for Managing Cognitive and Sleep Dysfunction in Preclinical Alzheimer's Disease
Background: Sleep disturbances, as a common symptom, can jeopardize the brain health and cognitive function and even lead to cognitive impairments in older adults.
- Conditions
- Sleep Disturbances, Aging, Cognitive Impairment, Mild
- Trial name
- NCT07298876
- Testing
- Low-intensity transcranial ultrasound stimulation
- Where
- Hong Kong
- Volunteers
- 20 people
- Sponsor
- Chinese University of Hong Kong
Alzheimers Disease
A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease
The purpose of this study was to test whether two investigational drugs called CAD106 and CNP520, administered separately, could slow down the onset and progression of clinical symptoms associated with Alzheimer's disease (AD) in…
- Trial name
- GS1 (NCT02565511)
- Testing
- CAD106 Immunotherapy, CNP520, Alum
- Where
- 129 sites in United States, Australia and 8 more
- Volunteers
- 480 people
- Sponsor
- Novartis Pharmaceuticals
Alzheimer Disease
Donanemab (LY3002813) Trial in Chinese Participants With Cognitively Unimpaired (Preclinical) Alzheimer's Disease
The main purpose of this study is to evaluate the effects of donanemab (LY3002813) versus placebo in Chinese participants who are at risk for decline of memory, language and physical ability to perform activities of daily living…
- Trial name
- NCT07571161
- Testing
- Donanemab
- Where
- 30 sites in China
- Volunteers
- 140 people
- Sponsor
- Eli Lilly and Company
Alzheimer Disease, Mild Cognitive Impairment
Flortaucipir PET Imaging in the Preclinical, Prodromal and Dementia Phases of Alzheimer's Disease
A Phase 1 study designed to evaluate imaging characteristics of flortaucipir in the preclinical, prodromal and dementia phases of Alzheimer's disease.
- Trial name
- NCT04468347
- Testing
- Flortaucipir F18, Brain PET scan
- Volunteers
- 89 people, healthy volunteers welcome
- Sponsor
- Avid Radiopharmaceuticals
Alzheimer Disease, Subjective Cognitive Decline
Neurofeedback Intervention for Preclinical Alzheimer's Disease
Alzheimer's disease (AD) is the most common form of neurodegenerative disorders leading to dementia. Currently, there has been no effective pharmacologic therapy for this disease.
- Conditions
- Alzheimer Disease, Subjective Cognitive Decline, Neurofeedback, Electroencephalogram
- Trial name
- NCT04300933
- Testing
- Electroencephalogram-based neurofeedback
- Where
- China
- Volunteers
- 50 people
- Sponsor
- XuanwuH 2
Alzheimer Disease, Mild Cognitive Impairment
Atlas of Retinal Imaging in Alzheimer's Study
The Atlas of Retinal Imaging in Alzheimer's (ARIAS) study is a 5-year study examining the natural history of retinal imaging biomarkers associated with disease risk, disease burden, and disease progression in Alzheimer's disease…
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment, Mild Dementia, Aging
- Trial name
- ARIAS (NCT03862222)
- Testing
- Retinal Imaging, Pupillometry, Contrast Sensitivity
- Where
- 4 sites in United States
- Volunteers
- 165 people, healthy volunteers welcome
- Sponsor
- University of Rhode Island
Alzheimers Disease
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
This study is a pre-screening process used to assess participants' potential eligibility for Roche interventional Alzheimer's disease studies.
- Trial name
- TRAVELLER (NCT07177352)
- Testing
- No Intervention
- Where
- 234 sites in United States, Argentina and 13 more
- Volunteers
- 80,000 people
- Sponsor
- Hoffmann-La Roche
Mobility Limitation, Fall Injury
Home-based HIFST for Older Adults to Prevent Functional Decline
After an injury, an older adult may experience changes to how they complete their daily activities and participate in physical activity.
- Conditions
- Mobility Limitation, Fall Injury, Slip and Fall
- Trial name
- NCT05266911
- Testing
- high-intensity functional strength training, Lower extremity stretching
- Where
- 2 sites in Canada
- Volunteers
- 24 people
- Sponsor
- McMaster University
Subjective Cognitive Concerns, Mild Cognitive Impairment
Digital Accessible Remote Olfactory Mediated Health Assessments for Preclinical AD
The goal of this study is to objectively test one's sense of smell, called olfaction, in participants with Subjective Cognitive Concerns (SCC), Mild Cognitive Impairment, Mild Behavioral Impairment (MBI), and age-matched…
- Conditions
- Subjective Cognitive Concerns, Mild Cognitive Impairment, Mild Behavioral Impairment, Healthy Aging
- Trial name
- NCT05881239
- Testing
- AROMHA Brain Health Test
- Where
- United States
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Alzheimer Disease, Late Onset, Mild Cognitive Impairment
Establish Diagnostic and Prognostic Models for Preclinical AD Patients Based on Multimodal MRI, Behavioral, Genetic, and Plasma Biomarkers
To establish the diagnostic and prognostic models that could help the preclinical identification of subjects at higher risk of clinical progression to mild cognitive impairment and dementia based on combined features of baseline…
- Conditions
- Alzheimer Disease, Late Onset, Mild Cognitive Impairment, Subjective Cognitive Decline
- Trial name
- NCT06561906
- Testing
- Multimodal magnetic resonance imaging scanning, behavioral, genetic and plasma biomarker testing
- Where
- China
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Alzheimer Disease, Preclinical Alzheimer's Disease
Amyloid Prediction in Early Stage Alzheimer's Disease Through Speech Phenotyping
The primary objective of the study is to evaluate whether a set of algorithms analysing acoustic and linguistic patterns of speech can detect amyloid-specific cognitive impairment in early stage Alzheimer's disease, as measured…
- Conditions
- Alzheimer Disease, Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease, Alzheimer's Disease (Incl Subtypes)
- Trial name
- AMYPRED-US (NCT04928976)
- Where
- United States
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- Novoic Limited
Alzheimer Disease, Alzheimer's Disease (Incl Subtypes)
Amyloid Prediction in Early Stage Alzheimer's Disease Through Speech Phenotyping - PAST Extension
The primary objective of the study is to evaluate whether a set of algorithms analysing acoustic and linguistic patterns of speech can detect amyloid-specific cognitive impairment in early stage Alzheimer's disease, based on…
- Conditions
- Alzheimer Disease, Alzheimer's Disease (Incl Subtypes), Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease
- Trial name
- PAST-US (NCT04937959)
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Novoic Limited
Alzheimer Disease, Cognitive Dysfunction, Cognitive Disorder
DIV-AD BARCELONA: Alzheimer's Blood-Based Biomakers for a Diverse Community
The DIV-AD study aims to find out whether levels of Alzheimer's disease markers in blood differ among the main ethnical groups living in central Barcelona.
- Conditions
- Alzheimer Disease, Cognitive Dysfunction, Cognitive Disorder, Dementia, Neurodegenerative Disease
- Trial name
- DIV-AD (NCT07521722)
- Where
- Spain
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Barcelonabeta Brain Research Center, Pasqual Maragall Foundation